(Pazona et al. 2005)
Design: Retrospective case series (therapy), evidence level: 3
Country: United States
Inclusion criteria Men who had radical retropubic prostatectomy, and then salvage radiotherapy for PSA progression (0.1 ng/ml or more). All were initially treated by the same surgeon between 1983 and 2003.
Exclusion criteria Men who had adjuvant therapy (hormonal therapy or radiotherapy). Men with missing follow up data.
Population number of patients = 223.
Interventions Salvage radiotherapy was given at different institutions. The details of EBRT were not available.
Outcomes PSA progression free survival.
Follow up Median time from RRP to PSA progression was 23 months (range 1 to 129).
Median follow-up from RRP was 104 months (range 7 to 225). Median follow-up from salvage radiotherapy was 56 months (range 0 to 188).
Results Analysis was done to compare the progression free survival of subgroups based on PSA level at salvage therapy, seminal vesicle (SVI) or lymph node involvement (LNI), and PSA doubling time (PSA-DT).
COMPARISON IN MEN WITH BIOCHEMICAL RECURRENCE AFTER PROSTATECTOMYSALVAGE RADIOTHERAPY WHEN PSA <1.3 NG/MLSALVAGE RADIOTHERAPY WHEN PSA >1.3 NG/MLOVERALL RESULT
5 year progression free survival43%32%Better if PSA < 1.3 ng/ml (p=0.03, log rank test)
COMPARISON IN MEN WITH BIOCHEMICAL RECURRENCE AFTER PROSTATECTOMYSALVAGE RADIOTHERAPY IN MEN WITH NO SVI OR LNISALVAGE RADIOTHERAPY IN MEN WITH SVI OR LNIOVERALL RESULT
5 year progression free survival46%20%Better if no SVI or LNI (p<0.01)
COMPARISON IN MEN WITH BIOCHEMICAL RECURRENCE AFTER PROSTATECTOMYSALVAGE RADIOTHERAPY IN MEN WITH PSA-DT > 10 MONTHSSALVAGE RADIOTHERAPY IN MEN WITH PSA-DT < 10 MONTHSOVERALL RESULT
5 year progression free survival48%33%Better if PSA-DT > 10 months (p=0.06)
General comments -

From: Chapter 5 –The Management of Relapse After Radical Treatment

Cover of Prostate Cancer
Prostate Cancer: Diagnosis and Treatment.
NICE Clinical Guidelines, No. 58.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.